[Management of immune-related toxicities associated with immune checkpoints inhibitors: Data from the multidisciplinary meeting « ToxImmun » in Eastern Occitania].

Gestion des toxicités induites par les inhibiteurs de checkpoint immunologique : données de la réunion de concertation pluridisciplinaire « ToxImmun » en Occitanie Est

V. Rivet (1, 2, 3) , X. Quantin (4) , J.L. Faillie (5, 2, 3) , C. Lesage (1, 2) , L. Meunier (1, 2, 3) , S. Faure (1, 2) , D. Hillaire-Buys (5, 2, 3) , C. Lesouder (5, 2) , S. Fabre (6) , E. Assenat (1, 2, 3) , P. Rullier (1, 2) , P. Guilpain (1, 2, 7) , A.T.J. Maria (1, 2, 7)

1 CHRU Montpellier - Hôpital Saint Eloi
2 CHRU Montpellier - Centre Hospitalier Régional Universitaire [Montpellier]
3 UM - Université de Montpellier
4 ICM - Institut régional de Cancérologie de Montpellier
5 CHU - Hôpital Lapeyronie [Montpellier]
6 Clinique Beau Soleil [Montpellier]
7 Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB)

Immune checkpoint inhibitors (ICIs) can cause numerous and complex immune-related adverse events whose management need a multidisciplinary approach. Herein, we investigated 114 requests, mostly concerning patients suffering from lung cancer, that were submitted to the « ToxImmun » multidisciplinary meeting in Eastern Occitania between December the 17th 2018 and January the 20th 2020. The leading reasons for the request concerned the putative causal link between immunotherapy and immune-toxicity and its management, followed by possible retreatment after temporary withdrawn because of adverse event, and finally the possibility to initiate ICIs in patients with pre-existing autoimmunity. Colitis, hepatitis and myocarditis were the most frequent immune-related adverse events (IRAEs), both all grade and grade 3-4. Sicca syndrome (with or without Sjogren criteria) was also frequent (26% of cases) and seems to be associated with severe toxicity and multi-toxicity. The mean time to first IRAE was 3.8 months, a time shortened with the use of anti-PD-L1 agents or ICI combination. A majority of requests came from initial evaluation by the internist confirming the early and main role of this specialty in the management of immunotoxicity. Expansion of this regional multidisciplinary meeting, coordinated by internists and medical oncologists, could improve management of immune-related adverse events for the patients' benefits.

Keywords: Cancérologie; Effets indésirables immuno-induits; Immune checkpoint inhibitors; Immune-related adverse event; Inhibiteur de checkpoint immunologique; Multidisciplinary meeting; Oncology; Pharmacovigilance; Pharmacovigilance.; Réunion de concertation pluridisciplinaire; Sjogren syndrome; Syndrome de Gougerot–Sjögren

Domains: Life Sciences [q-bio]

V. Rivet, X. Quantin, J.L. Faillie, C. Lesage, L. Meunier, et al.. Gestion des toxicités induites par les inhibiteurs de checkpoint immunologique : données de la réunion de concertation pluridisciplinaire « ToxImmun » en Occitanie Est. La Revue de Médecine Interne, 2021, 42 (5), pp.310-319. ⟨10.1016/j.revmed.2021.01.002⟩. ⟨hal-03664797⟩